Matthew Hawryluk
Director/Board Member bei PREDICTIVE ONCOLOGY INC.
Vermögen: 761 476 $ am 31.03.2024
Profil
Matthew J.
Hawryluk is an Independent Director at Predictive Oncology, Inc. and the Chief Business Officer & Executive Vice President at Gritstone bio, Inc. He was previously the Vice President-Corporate & Business Development at Foundation Medicine, Inc. Hawryluk received his undergraduate degree from the University of Notre Dame, his MBA from the Tepper School of Business, and his doctorate from the University of Pittsburgh School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GRITSTONE BIO, INC.
0,29% | 01.02.2024 | 286 880 ( 0,29% ) | 737 282 $ | 31.03.2024 |
PREDICTIVE ONCOLOGY INC
0,23% | 05.04.2024 | 9 488 ( 0,23% ) | 24 194 $ | 31.03.2024 |
Aktive Positionen von Matthew Hawryluk
| Unternehmen | Position | Beginn |
|---|---|---|
| GRITSTONE BIO, INC. | Corporate Officer/Principal | 01.11.2015 |
| PREDICTIVE ONCOLOGY INC. | Director/Board Member | 29.11.2022 |
Ehemalige bekannte Positionen von Matthew Hawryluk
| Unternehmen | Position | Ende |
|---|---|---|
| FOUNDATION MEDICINE INC | Corporate Officer/Principal | - |
Ausbildung von Matthew Hawryluk
| University of Notre Dame | Undergraduate Degree |
| Tepper School of Business | Masters Business Admin |
| University of Pittsburgh School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PREDICTIVE ONCOLOGY INC. | Health Technology |
| GRITSTONE BIO, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Foundation Medicine, Inc.
 Foundation Medicine, Inc. Medical/Nursing ServicesHealth Services Foundation Medicine, Inc. is a molecular information company, which engages in the provision of information on clinical treatment decisions for patients with cancer. The company was founded on January 10, 2010 and is headquartered in Cambridge, MA. | Health Services |
